The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | Using molecular profiling and genomic insights to improve the management of CMML
In this video, Eric Padron, MD, Moffitt Cancer Center, Tampa, FL, comments on the value of molecular profiling and genomic insights for improving the management of chronic myelomonocytic leukemia (CMML). Dr Padron highlights that repurposing approved therapies for related diseases with similar molecular profiles expands treatment options for patients with CMML, and that genetic mutations are prognostic, enabling the development of a prognostication tool that combines clinical, pathologic, and genetic data. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think the most important part of the genomics as it relates to CMML or any other rare disease is that because it’s so challenging to compel industry partners and perform clinical trials in the space, being able to repurpose therapies that may be approved for another type of disease or related disease that have a similar molecular profile that could work in the CMML opens the door for our patients to have a larger toolbox that we can use to treat them that otherwise we wouldn’t...
I think the most important part of the genomics as it relates to CMML or any other rare disease is that because it’s so challenging to compel industry partners and perform clinical trials in the space, being able to repurpose therapies that may be approved for another type of disease or related disease that have a similar molecular profile that could work in the CMML opens the door for our patients to have a larger toolbox that we can use to treat them that otherwise we wouldn’t. And so the most practical way that we use it is that way.
The second important thing is these mutations like myeloproliferative diseases, like all diseases in the myeloid neoplasm space, mutations are very prognostic. And so we were part of a model or part of the development of a model that we presented last year that leveraged both clinical, pathologic, and genetic data to devise a tool that we hope to be a standard for how we prognosticate and treat it.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
